An Exploratory, Prospective, Randomized, Pragmatic Open Label Cohort Study to Evaluate the Comparative Effectiveness of Eptinezumab in the United States
Latest Information Update: 30 May 2024
At a glance
- Drugs Eptinezumab (Primary) ; Botulinum-Toxin-A; Erenumab; Fremanezumab; Galcanezumab
- Indications Migraine
- Focus Therapeutic Use
- Acronyms EVEC
- Sponsors Lundbeck A/S
Most Recent Events
- 09 May 2023 Status changed from completed to discontinued.
- 28 Apr 2023 Status changed from active, no longer recruiting to completed.
- 07 Feb 2023 Planned End Date changed from 31 Dec 2023 to 30 Apr 2023.